# Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

> **NCT05012098** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Olfactory Neuroblastoma
- Esthesioneuroblastoma
- Neoplasm of the Nasal Cavity

## Interventions

- **DRUG:** Bintrafusp alfa/M7824
- **DRUG:** Ibuprofen
- **DIAGNOSTIC_TEST:** PET scan
- **DIAGNOSTIC_TEST:** CT scan
- **PROCEDURE:** Tumor tissue biopsy
- **DIAGNOSTIC_TEST:** Brain MRI
- **DIAGNOSTIC_TEST:** Dotate scan
- **DIAGNOSTIC_TEST:** PET FDG scan
- **DIAGNOSTIC_TEST:** Nuclear bone scan
- **DIAGNOSTIC_TEST:** EKG

## Key facts

- **NCT ID:** NCT05012098
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012098, "Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05012098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*